MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1245/s10434-026-20310-2

Медицинская библиотека · Annals of surgical oncology · 2026

Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study.

Vachtenheim Jiri, Casas-Mendez Fernando, Novysedlak Rene, Tavandzis Janis, Capkova Linda, Vajter Jaromir, Szkorupa Marek, Kultan Juraj, Taskova Alice, Koziar Vasakova Martina, Skala Martin, Svaton Martin, Maly Vilem, Sulc David, Hanke Ivo, Hrnciarik Michal, Mitas Ladislav, Bratova Monika, Tulinsky Lubomir, Cernekova Radoslava, Ozaniak Strizova Zuzana, Kuhn Matyas, Sepesi Boris, Palich Fucikova Jitka, Lischke Robert

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Neoadjuvant chemo-immunotherapy has transformed the treatment landscape for resectable non-small-cell lung cancer (NSCLC). However, real-world surgical data from nationwide European cohorts remain limited. This study evaluated surgical outcomes and practice patterns during the first year of nationwide implementation of neoadjuvant chemo-immunotherapy with nivolumab in the Czech Republic.

METHODS

This prospective, multicenter, observational cohort study included all consecutive patients with resectable programmed cell death ligand-1(PD-L1) ≥ 1% NSCLC treated according to the CheckMate 816 protocol (platinum-based chemotherapy plus nivolumab) at all eight accredited thoracic oncology centers in the Czech Republic between August 2023 and August 2024. Surgical and pathological outcomes were assessed.

RESULTS

Sixty-four patients initiated neoadjuvant therapy and 56 (87.5%) underwent resection. Minimally invasive surgery was attempted in 46.4% of cases, with an 11.5% conversion rate. Clavien-Dindo grade ≥ III complications occurred in 14.3%, with grade IIIb representing the highest severity. 30-day mortality was 0%. Although 90-day mortality was 5.4%, none of the deaths were directly attributable to surgery. R0 resection was achieved in 98.2%. In the intention-to-treat population, pathological complete response and major pathological response rates were 40.6% and 48.4%, respectively. Pathological complete response was significantly higher in squamous than in non-squamous NSCLC (66.7% vs. 27.6%; p = 0.003).

CONCLUSIONS

In this first nationwide cohort from a European country, early adoption of neoadjuvant chemo-immunotherapy with nivolumab in patients with resectable PD-L1 ≥ 1% NSCLC was associated with acceptable perioperative outcomes, high R0 resection rates, and substantial pathological response. These results demonstrate the successful adoption of a novel NSCLC treatment modality across a nationwide healthcare system.

Для цитирования: Vachtenheim Jiri, Casas-Mendez Fernando, Novysedlak Rene, Tavandzis Janis, Capkova Linda, Vajter Jaromir, Szkorupa Marek, Kultan Juraj, Taskova Alice, Koziar Vasakova Martina, Skala Martin, Svaton Martin, Maly Vilem, Sulc David, Hanke Ivo, Hrnciarik Michal, Mitas Ladislav, Bratova Monika, Tulinsky Lubomir, Cernekova Radoslava, Ozaniak Strizova Zuzana, Kuhn Matyas, Sepesi Boris, Palich Fucikova Jitka, Lischke Robert. Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study.. Annals of surgical oncology. 2026. DOI: 10.1245/s10434-026-20310-2.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.